SITE007-0103

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-07-01

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Decreased appetite — outcome: UNKNOWN; onset 2022-07-26 (study day 14); relationship: not assessed; serious criteria: life-threatening

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-26 (study day 14); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 19); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 19); relationship: not assessed

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 21); relationship: not assessed

Data queries

No data queries.